T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases.
Founded in 2022, the company is based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine.
Professor Allan Bradley has previously founded several companies including Kymab, a company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, which was acquired by Sanofi in 2021 for $1.45 billion.
T-Therapeutics has already raised investment from “a blue-chip syndicate of investors” to support its drug discovery efforts and prepare candidates for clinical development. It is currently building facilities, recruiting staff, and establishing its research operations.
Subscribe for alerts on new companies featured on Startups.Bio
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the latest funding activities and discover …